Euroopa Liit - eesti - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - transplantaadi tagasilükkamine - immunosupressandid - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Eesti - eesti - Ravimiamet

aktsiaselts kevelt - dinoprostoon - infusioonilahuse kontsentraat - 1mg 1ml 1ml 20tk

Eesti - eesti - Ravimiamet

orion corporation - östradiool - transdermaalne geel - 1mg 1g 0.5g 28tk; 1mg 1g 1g 28tk

Eesti - eesti - Ravimiamet

meda pharma gmbh & co. kg - fentanüül - bukaalravimkile - 400mcg 28tk; 400mcg 4tk; 400mcg 10tk

Eesti - eesti - Ravimiamet

meda pharma gmbh & co. kg - fentanüül - bukaalravimkile - 200mcg 28tk; 200mcg 10tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - sildenafiil - suus dispergeeruv ravimkile - 50mg 4tk; 50mg 12tk; 50mg 10tk; 50mg 8tk; 50mg 24tk; 50mg 1tk; 50mg 28tk; 50mg 20tk

Eesti - eesti - Ravimiamet

meda pharma gmbh & co. kg - fentanüül - bukaalravimkile - 1200mcg 28tk; 1200mcg 4tk; 1200mcg 3tk; 1200mcg 10tk

Eesti - eesti - Ravimiamet

meda pharma gmbh & co. kg - fentanüül - bukaalravimkile - 800mcg 4tk; 800mcg 10tk; 800mcg 28tk

Eesti - eesti - Ravimiamet

meda pharma gmbh & co. kg - fentanüül - bukaalravimkile - 600mcg 28tk; 600mcg 4tk; 600mcg 10tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - sildenafiil - suus dispergeeruv ravimkile - 75mg 2tk; 75mg 8tk; 75mg 4tk; 75mg 1tk; 75mg 10tk; 75mg 24tk; 75mg 20tk; 75mg 28tk; 75mg 16tk